ArticlemSystems2021
Identification and Differentiation of Pseudomonas Species in Field Samples Using an
Article in mSystems, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- The Caenorhabditis elegans microbiome impacts microsporidia infection through nutrient limitation and spore inactivation.Nature communications · 2026Article
- Development of a bioassay-guided genome mining approach for antifungal natural product discovery from pseudomonads.Scientific reports · 2026Article
- Gut Microbiota Dynamics in Hibernating and ActiveVeterinary sciences · 2025Article
- Insight into the phylogeny and antibiotic resistance ofFrontiers in microbiology · 2025Article
- Agricultural Soil as a Reservoir ofMicroorganisms · 2024Article
- Taxonomy ofmSystems · 2024Article
- Article
- DecodingFrontiers in cellular and infection microbiology · 2024Article
- Enhanced specificity of Bacillus metataxonomics using a tuf-targeted amplicon sequencing approach.ISME communications · 2023Article
- Taxonomic characterization ofMicrobiology spectrum · 2023Article
- Microbiota and Mitochondrial Sex-Dependent Imbalance in Fibromyalgia: A Pilot Descriptive Study.Neurology international · 2023Article
- Charting the Lipopeptidome of Nonpathogenic Pseudomonas.mSystems · 2023Article
- RibDif2: expanding amplicon analysis to full genomes.Bioinformatics advances · 2023Article
- RibDif: can individual species be differentiated by 16S sequencing?Bioinformatics advances · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Species of the genus Pseudomonas are used for several biotechnological purposes, including plant biocontrol and bioremediation. To exploit the Pseudomonas genus in environmental, agricultural, or industrial settings, the organisms must be profiled at the species level as their bioactivity potential differs markedly between species. Standard 16S rRNA gene amplicon profiling does not allow for accurate species differentiation. Thus, the purpose of this study was to develop an amplicon-based high-resolution method targeting a 760-nucleotide (nt) region of the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.